144 related articles for article (PubMed ID: 34299031)
1. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.
Jiao J; Sanchez JI; Thompson EJ; Mao X; McCormick JB; Fisher-Hoch SP; Futreal PA; Zhang J; Beretta L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299031
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
3. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics.
Jiao J; Kwan SY; Sabotta CM; Tanaka H; Veillon L; Warmoes MO; Lorenzi PL; Wang Y; Wei P; Hawk ET; Almeda JL; McCormick JB; Fisher-Hoch SP; Beretta L
Cancer Epidemiol Biomarkers Prev; 2021 Sep; 30(9):1643-1651. PubMed ID: 34155064
[TBL] [Abstract][Full Text] [Related]
4. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma.
Cai J; Chen L; Zhang Z; Zhang X; Lu X; Liu W; Shi G; Ge Y; Gao P; Yang Y; Ke A; Xiao L; Dong R; Zhu Y; Yang X; Wang J; Zhu T; Yang D; Huang X; Sui C; Qiu S; Shen F; Sun H; Zhou W; Zhou J; Nie J; Zeng C; Stroup EK; Zhang X; Chiu BC; Lau WY; He C; Wang H; Zhang W; Fan J
Gut; 2019 Dec; 68(12):2195-2205. PubMed ID: 31358576
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
Labgaa I; Villacorta-Martin C; D'Avola D; Craig AJ; von Felden J; Martins-Filho SN; Sia D; Stueck A; Ward SC; Fiel MI; Mahajan M; Tabrizian P; Thung SN; Ang C; Friedman SL; Llovet JM; Schwartz M; Villanueva A
Oncogene; 2018 Jul; 37(27):3740-3752. PubMed ID: 29628508
[TBL] [Abstract][Full Text] [Related]
7. Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma.
Luo B; Ma F; Liu H; Hu J; Rao L; Liu C; Jiang Y; Kuangzeng S; Lin X; Wang C; Lei Y; Si Z; Chen G; Zhou N; Liang C; Jiang F; Liu F; Dai W; Liu W; Gao Y; Li Z; Li X; Zhou G; Li B; Zhang Z; Nian W; Luo L; Liu X
BMC Med; 2022 Jan; 20(1):8. PubMed ID: 35027051
[TBL] [Abstract][Full Text] [Related]
8. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma.
Akuta N; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Suzuki Y; Kumada H
J Med Virol; 2020 Dec; 92(12):3604-3608. PubMed ID: 32100879
[TBL] [Abstract][Full Text] [Related]
9. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
Kaseb AO; Sánchez NS; Sen S; Kelley RK; Tan B; Bocobo AG; Lim KH; Abdel-Wahab R; Uemura M; Pestana RC; Qiao W; Xiao L; Morris J; Amin HM; Hassan MM; Rashid A; Banks KC; Lanman RB; Talasaz A; Mills-Shaw KR; George B; Haque A; Raghav KPS; Wolff RA; Yao JC; Meric-Bernstam F; Ikeda S; Kurzrock R
Clin Cancer Res; 2019 Oct; 25(20):6107-6118. PubMed ID: 31363003
[TBL] [Abstract][Full Text] [Related]
10. A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma.
Kim SC; Kim DW; Cho EJ; Lee JY; Kim J; Kwon C; Kim-Ha J; Hong SK; Choi Y; Yi NJ; Lee KW; Suh KS; Kim W; Kim W; Kim H; Kim YJ; Yoon JH; Yu SJ; Kim YJ
Mol Cancer; 2023 Oct; 22(1):164. PubMed ID: 37803338
[TBL] [Abstract][Full Text] [Related]
11. Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network.
Deng Z; Ji Y; Han B; Tan Z; Ren Y; Gao J; Chen N; Ma C; Zhang Y; Yao Y; Lu H; Huang H; Xu M; Chen L; Zheng L; Gu J; Xiong D; Zhao J; Gu J; Chen Z; Wang K
Genome Med; 2023 Nov; 15(1):93. PubMed ID: 37936230
[TBL] [Abstract][Full Text] [Related]
12. Detecting Liver Cancer Using Cell-Free DNA Fragmentomes.
Foda ZH; Annapragada AV; Boyapati K; Bruhm DC; Vulpescu NA; Medina JE; Mathios D; Cristiano S; Niknafs N; Luu HT; Goggins MG; Anders RA; Sun J; Meta SH; Thomas DL; Kirk GD; Adleff V; Phallen J; Scharpf RB; Kim AK; Velculescu VE
Cancer Discov; 2023 Mar; 13(3):616-631. PubMed ID: 36399356
[TBL] [Abstract][Full Text] [Related]
13. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.
Pairawan S; Hess KR; Janku F; Sanchez NS; Mills Shaw KR; Eng C; Damodaran S; Javle M; Kaseb AO; Hong DS; Subbiah V; Fu S; Fogelman DR; Raymond VM; Lanman RB; Meric-Bernstam F
Clin Cancer Res; 2020 Apr; 26(8):1924-1931. PubMed ID: 31852833
[TBL] [Abstract][Full Text] [Related]
14. Plasma Circulating Cell-free DNA in Advanced Hepatocellular Carcinoma Patients Treated With Radiation Therapy.
Kim DY; Cho EH; Kim JS; Chie EK; Kang HC
In Vivo; 2023; 37(5):2306-2313. PubMed ID: 37652507
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of dysplastic liver nodules using low-pass DNA sequencing and detection of chromosome arm-level abnormalities in blood-derived cell-free DNA.
Fateen W; Johnson PJ; Wood HM; Zhang H; He S; El-Meteini M; Wyatt JI; Aithal GP; Quirke P
J Pathol; 2021 Sep; 255(1):30-40. PubMed ID: 34028025
[TBL] [Abstract][Full Text] [Related]
16. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma.
Holmila R; Sklias A; Muller DC; Degli Esposti D; Guilloreau P; Mckay J; Sangrajrang S; Srivatanakul P; Hainaut P; Merle P; Herceg Z; Nogueira da Costa A
PLoS One; 2017; 12(3):e0174265. PubMed ID: 28333958
[TBL] [Abstract][Full Text] [Related]
17. Developments and current status of cell-free DNA in the early detection and management of hepatocellular carcinoma.
Du S; Cao K; Yan Y; Wang Y; Wang Z; Lin D
J Gastroenterol Hepatol; 2024 Feb; 39(2):231-244. PubMed ID: 37990622
[TBL] [Abstract][Full Text] [Related]
18. Advances in biomarker discovery using circulating cell-free DNA for early detection of hepatocellular carcinoma.
Liu M; Zhang Z; Zhang W; Liu SM
WIREs Mech Dis; 2023; 15(3):e1598. PubMed ID: 36697374
[TBL] [Abstract][Full Text] [Related]
19. Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis.
Yiğit B; Boyle M; Özler O; Erden N; Tutucu F; Hardy T; Bergmann C; Distler JHW; Adalı G; Dayangaç M; Mann DA; Zeybel M; Mann J
Gut; 2018 Oct; 67(10):1907-1908. PubMed ID: 29353249
[No Abstract] [Full Text] [Related]
20. Genetic Analyses of Primary Liver Cancer Cell Lines: Correspondence With Morphological Features of Original Tumors.
Akiba J; Ogasawara S; Yano H
Cancer Genomics Proteomics; 2024; 21(3):260-271. PubMed ID: 38670592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
